Skip to content

Impact of medicines on red blood cells

Frequency and characterization of drug induced antibodies against red cell antigen

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065162
Enrollment
385
Registered
2024-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D590- Drug-induced autoimmune hemolyticanemia

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Kasturba Medical College Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Including all patients who are getting admitted under department of Infectious Diseases, who are on antimicrobials

Exclusion criteria

Exclusion criteria: Excluding patients with known cases of 1. Inherited hemolytic anemia like sickle cell anemia, thalassemia, hereditary spherocytosis etc 2. Autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis etc 3. Cases of poisoning like Arsenic, Copper 4. Non hemolytic anemia like iron deficiency anemia, anemia due to chronic disease, chronic kidney disease, bone marrow dysfunction 5. All other causes of hemolysis

Design outcomes

Primary

MeasureTime frame
Frequency of antibodies produced to red cell antigen in patients on antimicrobials can be determined. This will allow for a close monitoring of the patient before the occurrence of serious hemolysis. It will also help the treating doctor to decide on how frequently a patient should be monitored for clinical evidence of hemolysisTimepoint: Baseline and day 7

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDeepika Chenna

Kasturba Medical College Manipal

deepu.kkd@gmail.com9901470899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026